Novartis skin cancer drug shrinks tumors in Phase II trialReuters UKZURICH (Reuters) – An experimental drug from Novartis markedly shrank tumors in patients with advanced basal cell carcinoma, the most common form of skin cancer, according to the results of a mid-stage study published on Sunday. Basal cell carcinoma …Pivotal data for Novartis’ investigational compound LDE225 show marked tumor …MarketWatchall 6 news articles …Read Full Story
Novartis skin cancer drug shrinks tumors in Phase II trial - Reuters UK
Real Estate of Cebu
